Source: ThinkstockUntil about 2008 or so, discussion about the future price of crude oil was directed by the concept of peak oil. That is, when does the world reach peak production, after which the price of crude will skyrocket. In less than a decade, the discussion is now focused on the concept of “peak demand,” the point at which global demand for crude begins to decline.
The recent Oil & Money conference in London sharpened the focus on peak demand. Saudi Arabia’s minister of energy and industry, Khalid Al-Falih, told conference attendees that cutbacks in capital spending on exploration, forced on the industry by low prices for the past twoyears, could mean that shortfalls in supply are coming.
Exxon Mobil Corp. (NYSE: XOM) CEO Rex Tillerson disagreed:
Top 5 Low Price Stocks To Buy Right Now: Prima BioMed Ltd(PBMD)
- [By Monica Gerson]
Prima Biomed (NASDAQ: PBMD) shares dipped 38.59% to touch a new 52-week low of $1.44 after the company reported top-line analysis of CVac Phase 2 trial.
- [By Monica Gerson]
Prima Biomed (NASDAQ: PBMD) dropped 38.17% to $1.45 after the company reported top-line analysis of CVac Phase 2 trial.
Tower Group International (NASDAQ: TWGP) plummeted 24.31% to $10.49. Tower Group announced its plans to release its Q2 results during the week of October 7, 2013. FBR Capital downgraded the stock from Outperform to Market Perform.
Top 5 Low Price Stocks To Buy Right Now: IF Bancorp, Inc.(IROQ)
- [By Max Byerly]
News stories about IF Bancorp (NASDAQ:IROQ) have been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. IF Bancorp earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave news coverage about the savings and loans company an impact score of 47.5310825195986 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Top 5 Low Price Stocks To Buy Right Now: Sinovac Biotech Ltd.(SVA)
- [By Monica Gerson]
Sinovac Biotech Ltd. (NASDAQ: SVA) is expected to post its quarterly earnings.
Supercom Ltd (NASDAQ: SPCB) is estimated to post its quarterly earnings at $0.15 per share on revenue of $9.03 million.
Top 5 Low Price Stocks To Buy Right Now: Briggs & Stratton Corporation(BGG)
- [By Lisa Levin]
Check out these big penny stock gainers and losers
Check-Cap Ltd. (NASDAQ: CHEK) fell 23.3 percent to $9.87 in pre-market trading after declining 13.45 percent on Wednesday.
SunCoke Energy Partners, L.P. (NYSE: SXCP) fell 12.8 percent to $16.00 in pre-market trading after reporting Q1 results.
Briggs & Stratton Corporation (NYSE: BGG) fell 11 percent to $17.55 in pre-market trading after the company posted mixed Q3 results and lowered its FY18 guidance.
New Gold Inc. (NYSE: NGD) fell 8.4 percent to $2.30 in pre-market trading following downbeat Q1 results.
Quality Care Properties, Inc. (NYSE: QCP) fell 8.2 percent to $20.85 in pre-market trading. Welltower announced plans to acquire QCP for $20.75 per share in cash.
China Customer Relations Centers Inc. (NASDAQ: CCRC) shares fell 7.5 percent to $17.25 in pre-market trading after climbing 18.73 percent on Wednesday.
Nokia Corporation (NYSE: NOK) shares fell 5.7 percent to $5.58 in pre-market trading after reporting Q1 results.
eBay Inc. (NASDAQ: EBAY) fell 5.6 percent to $38.66 in pre-market trading following Q1 results.
- [By ]
For his “Executive Decision” segment, Cramer spoke with Todd Teske, chairman, president and CEO of Briggs & Stratton (BGG) , the small-engine maker that posted a penny-a-share earnings beat on Wednesday, but saw shares fall 11% on lighter-than-expected revenues and a cut in the company’s full-year guidance.
Top 5 Low Price Stocks To Buy Right Now: CytRx Corporation(CYTR)
- [By Roberto Pedone]
Another under-$10 biotechnology player that’s starting to trend within range of triggering a major breakout trade is CytRx (CYTR), which has an oncology pipeline that includes two programs in clinical development for cancer indications: aldoxorubicin and tamibarotene. This stock has been moving to the upside during the last three months, with shares up by 21%.
If you take a look at the chart for CytRx, you’ll notice that this stock has been trending sideways inside of a consolidation chart pattern for the last two months, with shares moving between $2.27 on the downside and $2.68 on the upside. That consolidation pattern has occurred right above this stock’s 50-day and 200-day moving averages. Shares of CYTR have now started to break out above some near-term overhead resistance at $2.49 a share. That move is quickly pushing CYTR within range of triggering an even bigger breakout trade above the upper-end of its recent sideways trading chart pattern.
Market players should now look for long-biased trades in CYTR if it manages to break out above some near-term overhead resistance levels at $2.68 to $2.80 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 154,838 shares. If that breakout triggers soon, then CYTR will set up to re-test or possibly take out its next major overhead resistance levels at $3.20 to $4 a share.
Traders can look to buy CYTR off any weakness to anticipate that breakout and simply use a stop that sits right below its 200-day at $2.33 a share or below more support at $2.27 a share. One can also buy CYTR off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.